Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates

The objective of this study was to compare the disintegration times among Canadian-marketed brand (alendronate 70 mg, alendronate 70 mg plus vitamin D 5600 IU, and risedronate 35 mg) and generic (Novo-alendronate 70 mg and Apo-alendronate 70 mg) once-weekly dosed bisphosphonates. All disintegration...

Full description

Saved in:
Bibliographic Details
Main Authors: Wojciech P. Olszynski, Jonathan D. Adachi, K. Shawn Davison
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Journal of Osteoporosis
Online Access:http://dx.doi.org/10.1155/2014/420451
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832558210025783296
author Wojciech P. Olszynski
Jonathan D. Adachi
K. Shawn Davison
author_facet Wojciech P. Olszynski
Jonathan D. Adachi
K. Shawn Davison
author_sort Wojciech P. Olszynski
collection DOAJ
description The objective of this study was to compare the disintegration times among Canadian-marketed brand (alendronate 70 mg, alendronate 70 mg plus vitamin D 5600 IU, and risedronate 35 mg) and generic (Novo-alendronate 70 mg and Apo-alendronate 70 mg) once-weekly dosed bisphosphonates. All disintegration tests were performed with a Vanderkamp Disintegration Tester. Disintegration was deemed to have occurred when no residue of the tablet, except fragments of insoluble coating or capsule shell, was visible. Eighteen to 20 samples were tested for each bisphosphonate group. The mean (±standard deviation) disintegration times were significantly P<0.05 faster for Apo-alendronate (26±5.6 seconds) and Novo-alendronate (13±1.1 seconds) as compared to brand alendronate (147±50.5 seconds), brand alendronate plus vitamin D (378±60.5 seconds), or brand risedronate (101±20.6 seconds). The significantly faster disintegration of the generic tablets as compared to the brand bisphosphonates may have concerning safety and effectiveness implications for patients administering these therapies.
format Article
id doaj-art-e2b37a61966d4cdab60208aa5df54103
institution Kabale University
issn 2090-8059
2042-0064
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series Journal of Osteoporosis
spelling doaj-art-e2b37a61966d4cdab60208aa5df541032025-02-03T01:33:01ZengWileyJournal of Osteoporosis2090-80592042-00642014-01-01201410.1155/2014/420451420451Differences in In Vitro Disintegration Time among Canadian Brand and Generic BisphosphonatesWojciech P. Olszynski0Jonathan D. Adachi1K. Shawn Davison2Saskatoon Osteoporosis Centre and Department of Medicine, University of Saskatchewan, Suite 103, 39-23rd Street East, Saskatoon, SK, S7K 0H6, CanadaDepartment of Medicine, St. Joseph’s Hospital, McMaster University, 501-25 Charlton Avenue E., Hamilton, ON, L8N 1Y2, CanadaUniversity of Victoria, P.O. Box 1700 STN CSC, Victoria, BC, V8W 2Y2, CanadaThe objective of this study was to compare the disintegration times among Canadian-marketed brand (alendronate 70 mg, alendronate 70 mg plus vitamin D 5600 IU, and risedronate 35 mg) and generic (Novo-alendronate 70 mg and Apo-alendronate 70 mg) once-weekly dosed bisphosphonates. All disintegration tests were performed with a Vanderkamp Disintegration Tester. Disintegration was deemed to have occurred when no residue of the tablet, except fragments of insoluble coating or capsule shell, was visible. Eighteen to 20 samples were tested for each bisphosphonate group. The mean (±standard deviation) disintegration times were significantly P<0.05 faster for Apo-alendronate (26±5.6 seconds) and Novo-alendronate (13±1.1 seconds) as compared to brand alendronate (147±50.5 seconds), brand alendronate plus vitamin D (378±60.5 seconds), or brand risedronate (101±20.6 seconds). The significantly faster disintegration of the generic tablets as compared to the brand bisphosphonates may have concerning safety and effectiveness implications for patients administering these therapies.http://dx.doi.org/10.1155/2014/420451
spellingShingle Wojciech P. Olszynski
Jonathan D. Adachi
K. Shawn Davison
Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates
Journal of Osteoporosis
title Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates
title_full Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates
title_fullStr Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates
title_full_unstemmed Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates
title_short Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates
title_sort differences in in vitro disintegration time among canadian brand and generic bisphosphonates
url http://dx.doi.org/10.1155/2014/420451
work_keys_str_mv AT wojciechpolszynski differencesininvitrodisintegrationtimeamongcanadianbrandandgenericbisphosphonates
AT jonathandadachi differencesininvitrodisintegrationtimeamongcanadianbrandandgenericbisphosphonates
AT kshawndavison differencesininvitrodisintegrationtimeamongcanadianbrandandgenericbisphosphonates